Business & Finance
Tue, February 15, 2011Mon, February 14, 2011Sun, February 13, 2011Sat, February 12, 2011Fri, February 11, 2011Thu, February 10, 2011Wed, February 9, 2011Tue, February 8, 2011Mon, February 7, 2011Sun, February 6, 2011Sat, February 5, 2011Fri, February 4, 2011VICTHOM COMMENTS ON THE RECENT MARKET ACTIVITY
//business-finance.news-articles.net/content/201 .. thom-comments-on-the-recent-market-activity.html
Published in Business and Finance on Wednesday, February 9th 2011 at 14:40 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
QUEBEC, Feb. 9 /CNW Telbec/ - Victhom Human Bionics Inc. ("Victhom" or the "Company", TSX-V: VHB) - At the request of Market Surveillance, the Company wishes to comment on the recent and unusual trading activity in its common shares. The Company is not aware of any specific information not currently disclosed which might explain the recent trading activity and increase in the market price of its shares. However, the Company would like to inform its investors that its partner, Ossur, during its investors conference call held yesterday concurrent with the release of its 2010 annual financial statements, reconfirmed the information previously announced by the Company that the Power Knee Second Generation would become commercially available in 2011.
In addition and as previously announced by Victhom in its Q-3 press release, Neurostream Technologies, General Partnership has not yet achieved a milestone as per the partnership agreement, a situation that is dependent on a number of factors that are not entirely under the Company's control. The Company's partner has continued to fund Neurostream's operations on a voluntary basis.
About Victhom
Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom Biotronix business developed the Power Knee, the world's first and only motor-powered, artificially intelligent prosthesis for above-knee amputees. The Power Knee is commercialized by Ossur, a global leader in the orthotics and prosthetics ("O&P") market. Victhom also has a 44.4% interest in Neurostream Technologies, General Partnership, a joint venture with Otto Bock HealthCare, whose objective is to bring to market the Neurostep® System, and to develop neuromodulation products in other indications such as sleep apnea.
FORWARD-LOOKING STATEMENTS
Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
